Eli Lilly and Co (NEOE:LLY)
C$ 30.07 -0.05 (-0.17%) Market Cap: 1.06 Tn Enterprise Value: 1.10 Tn PE Ratio: 87.15 PB Ratio: 50.94 GF Score: 68/100

Eli Lilly and Co at Bank of America Global Research Healthcare Conference (Virtual) Transcript

May 11, 2021 / 01:30PM GMT
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Okay, good morning. Welcome to the first day of the BofA Virtual Vegas Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. And I have Alec from my team with me on video as well.

we're thrilled to have with us Lilly. And speaking on behalf of Lilly, we have Mike Mason, Senior Vice President, Lilly Diabetes. Mike, thanks for coming.

Michael B. Mason
Eli Lilly and Company - Senior VP & President of Lilly Diabetes

Thanks. It's great to be here. I appreciate everyone's interest in Lilly Diabetes.

Questions & Answers

Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Right. So we're going to do some questions here between Alec and I, and let's get right into it. So Mike, when you think about what happened last year with COVID and you guys had a really good first quarter, just help walk us through kind of the first quarter of 2021. Coming out of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot